BindingDB logo
myBDB logout

Patent code US10239835

Compile Data Set for Download or QSAR
Found 142 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370772
PNG
(US10239835, Example 00324)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1ccc(O)cn1
Show InChI InChI=1/C20H23FN2O3/c21-15-1-4-17(5-2-15)26-18-7-13-10-23(11-14(13)8-18)12-20(25)19-6-3-16(24)9-22-19/h1-6,9,13-14,18,20,24-25H,7-8,10-12H2/t13-,14+,18+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 4.41n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370754
PNG
(US10239835, Example 00306)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1F)c1ccc(O)cc1
Show InChI InChI=1/C21H24FNO3/c22-19-3-1-2-4-21(19)26-18-9-15-11-23(12-16(15)10-18)13-20(25)14-5-7-17(24)8-6-14/h1-8,15-16,18,20,24-25H,9-13H2/t15-,16+,18+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 4.44n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370814
PNG
(US10239835, Example 00365)
Show SMILES O[C@H](CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1)c1ccc(O)cn1
Show InChI InChI=1/C20H24N2O3/c23-16-6-7-19(21-10-16)20(24)13-22-11-14-8-18(9-15(14)12-22)25-17-4-2-1-3-5-17/h1-7,10,14-15,18,20,23-24H,8-9,11-13H2/t14-,15+,18+,20-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 5.24n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370813
PNG
(US10239835, Example 00364)
Show SMILES O[C@@H](CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1)c1ccc(O)cn1
Show InChI InChI=1/C20H24N2O3/c23-16-6-7-19(21-10-16)20(24)13-22-11-14-8-18(9-15(14)12-22)25-17-4-2-1-3-5-17/h1-7,10,14-15,18,20,23-24H,8-9,11-13H2/t14-,15+,18+,20-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 5.25n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370756
PNG
(US10239835, Example 00308)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1)c1ccc(O)cn1
Show InChI InChI=1/C20H24N2O3/c23-16-6-7-19(21-10-16)20(24)13-22-11-14-8-18(9-15(14)12-22)25-17-4-2-1-3-5-17/h1-7,10,14-15,18,20,23-24H,8-9,11-13H2/t14-,15+,18+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 5.72n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370745
PNG
(US10239835, Example 00297)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1)c1ccc(O)cc1
Show InChI InChI=1/C21H25NO3/c23-18-8-6-15(7-9-18)21(24)14-22-12-16-10-20(11-17(16)13-22)25-19-4-2-1-3-5-19/h1-9,16-17,20-21,23-24H,10-14H2/t16-,17+,20+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 5.96n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370743
PNG
(US10239835, Example 00295)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1F)c1ccc(O)cn1
Show InChI InChI=1/C20H23FN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,19,24-25H,7-8,10-12H2/t13-,14+,16+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 6.20n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370781
PNG
(US10239835, Example 00333)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1F)c1ccc(O)cn1
Show InChI InChI=1/C20H22F2N2O3/c21-14-1-4-20(17(22)7-14)27-16-5-12-9-24(10-13(12)6-16)11-19(26)18-3-2-15(25)8-23-18/h1-4,7-8,12-13,16,19,25-26H,5-6,9-11H2/t12-,13+,16+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 6.81n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370815
PNG
(US10239835, Example 00366)
Show SMILES O[C@@H](CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1F)c1ccc(O)cn1
Show InChI InChI=1/C20H23FN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,19,24-25H,7-8,10-12H2/t13-,14+,16+,19-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 8.30n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370816
PNG
(US10239835, Example 00367)
Show SMILES O[C@H](CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1F)c1ccc(O)cn1
Show InChI InChI=1/C20H23FN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,19,24-25H,7-8,10-12H2/t13-,14+,16+,19-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 8.5n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370769
PNG
(US10239835, Example 00321)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1F)c1ccc(O)cc1
Show InChI InChI=1/C21H23F2NO3/c22-16-3-6-21(19(23)9-16)27-18-7-14-10-24(11-15(14)8-18)12-20(26)13-1-4-17(25)5-2-13/h1-6,9,14-15,18,20,25-26H,7-8,10-12H2/t14-,15+,18+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 8.62n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370797
PNG
(US10239835, Example 00349)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccc(F)c1F)c1ccc(O)cn1
Show InChI InChI=1/C20H22F2N2O3/c21-16-2-1-3-19(20(16)22)27-15-6-12-9-24(10-13(12)7-15)11-18(26)17-5-4-14(25)8-23-17/h1-5,8,12-13,15,18,25-26H,6-7,9-11H2/t12-,13+,15+,18?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 8.78n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370802
PNG
(US10239835, Example 00354)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Sc1ccccc1)c1ccc(O)cc1
Show InChI InChI=1/C21H25NO2S/c23-18-8-6-15(7-9-18)21(24)14-22-12-16-10-20(11-17(16)13-22)25-19-4-2-1-3-5-19/h1-9,16-17,20-21,23-24H,10-14H2/t16-,17+,20+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 9.36n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370768
PNG
(US10239835, Example 00320)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1c(F)cccc1F)c1ccc(O)cn1
Show InChI InChI=1/C20H22F2N2O3/c21-16-2-1-3-17(22)20(16)27-15-6-12-9-24(10-13(12)7-15)11-19(26)18-5-4-14(25)8-23-18/h1-5,8,12-13,15,19,25-26H,6-7,9-11H2/t12-,13+,15+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 9.60n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370744
PNG
(US10239835, Example 00296)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1
Show InChI InChI=1/C21H23NO3/c23-18-8-6-15(7-9-18)21(24)14-22-12-16-10-20(11-17(16)13-22)25-19-4-2-1-3-5-19/h1-9,16-17,20,23H,10-14H2/t16-,17+,20+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 10.7n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370676
PNG
(US10239835, Example 00228)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1ccc(O)cc1
Show InChI InChI=1/C21H24FNO3/c22-17-3-7-19(8-4-17)26-20-9-15-11-23(12-16(15)10-20)13-21(25)14-1-5-18(24)6-2-14/h1-8,15-16,20-21,24-25H,9-13H2/t15-,16+,20+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 13n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370678
PNG
(US10239835, Example 00230)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)c(F)c1)c1ccc(O)cc1
Show InChI InChI=1/C21H23F2NO3/c22-19-6-5-17(9-20(19)23)27-18-7-14-10-24(11-15(14)8-18)12-21(26)13-1-3-16(25)4-2-13/h1-6,9,14-15,18,21,25-26H,7-8,10-12H2/t14-,15+,18+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 14n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370782
PNG
(US10239835, Example 00334)
Show SMILES Cc1ccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cn4)C[C@H]3C2)c(F)c1
Show InChI InChI=1/C21H25FN2O3/c1-13-2-5-21(18(22)6-13)27-17-7-14-10-24(11-15(14)8-17)12-20(26)19-4-3-16(25)9-23-19/h2-6,9,14-15,17,20,25-26H,7-8,10-12H2,1H3/t14-,15+,17+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 14.4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370755
PNG
(US10239835, Example 00307)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1F
Show InChI InChI=1/C21H22FNO3/c22-19-3-1-2-4-21(19)26-18-9-15-11-23(12-16(15)10-18)13-20(25)14-5-7-17(24)8-6-14/h1-8,15-16,18,24H,9-13H2/t15-,16+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 16.8n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370681
PNG
(US10239835, Example 00233)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)c(F)c1)c1ccc(O)cn1
Show InChI InChI=1/C20H22F2N2O3/c21-17-3-2-15(7-18(17)22)27-16-5-12-9-24(10-13(12)6-16)11-20(26)19-4-1-14(25)8-23-19/h1-4,7-8,12-13,16,20,25-26H,5-6,9-11H2/t12-,13+,16+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 17.8n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370727
PNG
(US10239835, Example 00279)
Show SMILES OC(CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1ccc(O)cc1
Show InChI InChI=1/C21H24FNO3/c22-17-3-7-19(8-4-17)26-20-9-15-11-23(12-16(15)10-20)13-21(25)14-1-5-18(24)6-2-14/h1-8,15-16,20-21,24-25H,9-13H2/t15-,16+,20-,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 17.8n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370694
PNG
(US10239835, Example 00246)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(cc1)C#N)c1ccc(O)cn1
Show InChI InChI=1/C21H23N3O3/c22-9-14-1-4-18(5-2-14)27-19-7-15-11-24(12-16(15)8-19)13-21(26)20-6-3-17(25)10-23-20/h1-6,10,15-16,19,21,25-26H,7-8,11-13H2/t15-,16+,19+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 18n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370809
PNG
(US10239835, Example 00361)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Sc1ccc(F)cc1)c1ccc(O)cc1
Show InChI InChI=1/C21H24FNO2S/c22-17-3-7-19(8-4-17)26-20-9-15-11-23(12-16(15)10-20)13-21(25)14-1-5-18(24)6-2-14/h1-8,15-16,20-21,24-25H,9-13H2/t15-,16+,20+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 19.2n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370817
PNG
(US10239835, Example 00368)
Show SMILES O[C@@H](CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccnc1F)c1ccc(O)cn1
Show InChI InChI=1/C19H22FN3O3/c20-19-18(2-1-5-21-19)26-15-6-12-9-23(10-13(12)7-15)11-17(25)16-4-3-14(24)8-22-16/h1-5,8,12-13,15,17,24-25H,6-7,9-11H2/t12-,13+,15+,17-/s2
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 20n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370812
PNG
(US10239835, Example 00363)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Sc1ccccc1F)c1ccc(O)cn1
Show InChI InChI=1/C20H23FN2O2S/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,19,24-25H,7-8,10-12H2/t13-,14+,16+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 20.6n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370749
PNG
(US10239835, Example 00301)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccnc1F)c1ccc(O)cn1
Show InChI InChI=1/C19H22FN3O3/c20-19-18(2-1-5-21-19)26-15-6-12-9-23(10-13(12)7-15)11-17(25)16-4-3-14(24)8-22-16/h1-5,8,12-13,15,17,24-25H,6-7,9-11H2/t12-,13+,15+,17?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 20.9n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370757
PNG
(US10239835, Example 00309)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccnc1F)c1ccc(O)c(F)c1
Show InChI InChI=1/C20H22F2N2O3/c21-16-8-12(3-4-17(16)25)18(26)11-24-9-13-6-15(7-14(13)10-24)27-19-2-1-5-23-20(19)22/h1-5,8,13-15,18,25-26H,6-7,9-11H2/t13-,14+,15+,18?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 21.7n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370784
PNG
(US10239835, Example 00336)
Show SMILES Cc1cccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cn4)C[C@H]3C2)c1F
Show InChI InChI=1/C21H25FN2O3/c1-13-3-2-4-20(21(13)22)27-17-7-14-10-24(11-15(14)8-17)12-19(26)18-6-5-16(25)9-23-18/h2-6,9,14-15,17,19,25-26H,7-8,10-12H2,1H3/t14-,15+,17+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 23.4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370794
PNG
(US10239835, Example 00346)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1c(F)cccc1F)c1ccc(O)cc1
Show InChI InChI=1/C21H23F2NO3/c22-18-2-1-3-19(23)21(18)27-17-8-14-10-24(11-15(14)9-17)12-20(26)13-4-6-16(25)7-5-13/h1-7,14-15,17,20,25-26H,8-12H2/t14-,15+,17+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 26.3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370801
PNG
(US10239835, Example 00353)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Sc1ccccc1
Show InChI InChI=1/C21H23NO2S/c23-18-8-6-15(7-9-18)21(24)14-22-12-16-10-20(11-17(16)13-22)25-19-4-2-1-3-5-19/h1-9,16-17,20,23H,10-14H2/t16-,17+,20+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 26.7n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370767
PNG
(US10239835, Example 00319)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1c(F)cccc1F
Show InChI InChI=1/C21H21F2NO3/c22-18-2-1-3-19(23)21(18)27-17-8-14-10-24(11-15(14)9-17)12-20(26)13-4-6-16(25)7-5-13/h1-7,14-15,17,25H,8-12H2/t14-,15+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 29.3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370714
PNG
(US10239835, Example 00266)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1ccc(O)c(F)n1
Show InChI InChI=1/C20H22F2N2O3/c21-14-1-3-15(4-2-14)27-16-7-12-9-24(10-13(12)8-16)11-19(26)17-5-6-18(25)20(22)23-17/h1-6,12-13,16,19,25-26H,7-11H2/t12-,13+,16+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 30.2n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370722
PNG
(US10239835, Example 00274)
Show SMILES OC(CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1ccc(O)c(F)c1
Show InChI InChI=1/C21H23F2NO3/c22-16-2-4-17(5-3-16)27-18-7-14-10-24(11-15(14)8-18)12-21(26)13-1-6-20(25)19(23)9-13/h1-6,9,14-15,18,21,25-26H,7-8,10-12H2/t14-,15+,18-,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 30.5n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370740
PNG
(US10239835, Example 00292)
Show SMILES OC(CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1ccc(F)c(F)c1)c1ccc(O)cn1
Show InChI InChI=1/C20H22F2N2O3/c21-17-3-2-15(7-18(17)22)27-16-5-12-9-24(10-13(12)6-16)11-20(26)19-4-1-14(25)8-23-19/h1-4,7-8,12-13,16,20,25-26H,5-6,9-11H2/t12-,13+,16-,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 37.6n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370800
PNG
(US10239835, Example 00352)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1Cl)c1ccc(O)cn1
Show InChI InChI=1/C20H23ClN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,19,24-25H,7-8,10-12H2/t13-,14+,16+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 38n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370765
PNG
(US10239835, Example 00317)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1F
Show InChI InChI=1/C21H21F2NO3/c22-16-3-6-21(19(23)9-16)27-18-7-14-10-24(11-15(14)8-18)12-20(26)13-1-4-17(25)5-2-13/h1-6,9,14-15,18,25H,7-8,10-12H2/t14-,15+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 41.1n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370711
PNG
(US10239835, Example 00263)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)c(F)c4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H26FNO4/c1-27-17-3-5-18(6-4-17)28-19-8-15-11-24(12-16(15)9-19)13-22(26)14-2-7-21(25)20(23)10-14/h2-7,10,15-16,19,22,25-26H,8-9,11-13H2,1H3/t15-,16+,19+,22?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 41.5n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370698
PNG
(US10239835, Example 00250)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cc4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H25NO4/c1-26-19-6-8-20(9-7-19)27-21-10-16-12-23(13-17(16)11-21)14-22(25)15-2-4-18(24)5-3-15/h2-9,16-17,21,24H,10-14H2,1H3/t16-,17+,21+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 46.4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370675
PNG
(US10239835, Example 00227)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1
Show InChI InChI=1/C21H22FNO3/c22-17-3-7-19(8-4-17)26-20-9-15-11-23(12-16(15)10-20)13-21(25)14-1-5-18(24)6-2-14/h1-8,15-16,20,24H,9-13H2/t15-,16+,20+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 47n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370702
PNG
(US10239835, Example 00254)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(cc1)C#N)c1ccc(O)cc1
Show InChI InChI=1/C22H24N2O3/c23-11-15-1-7-20(8-2-15)27-21-9-17-12-24(13-18(17)10-21)14-22(26)16-3-5-19(25)6-4-16/h1-8,17-18,21-22,25-26H,9-10,12-14H2/t17-,18+,21+,22?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 47.4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370787
PNG
(US10239835, Example 00339)
Show SMILES COc1cccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cn4)C[C@H]3C2)c1F
Show InChI InChI=1/C21H25FN2O4/c1-27-19-3-2-4-20(21(19)22)28-16-7-13-10-24(11-14(13)8-16)12-18(26)17-6-5-15(25)9-23-17/h2-6,9,13-14,16,18,25-26H,7-8,10-12H2,1H3/t13-,14+,16+,18?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 50.8n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370712
PNG
(US10239835, Example 00264)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cc4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H27NO4/c1-26-19-6-8-20(9-7-19)27-21-10-16-12-23(13-17(16)11-21)14-22(25)15-2-4-18(24)5-3-15/h2-9,16-17,21-22,24-25H,10-14H2,1H3/t16-,17+,21+,22?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 51.6n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370705
PNG
(US10239835, Example 00257)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccnc1)c1ccc(O)c(F)c1
Show InChI InChI=1/C20H23FN2O3/c21-18-8-13(3-4-19(18)24)20(25)12-23-10-14-6-17(7-15(14)11-23)26-16-2-1-5-22-9-16/h1-5,8-9,14-15,17,20,24-25H,6-7,10-12H2/t14-,15+,17+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 52.1n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370721
PNG
(US10239835, Example 00273)
Show SMILES Oc1ccc(cc1F)C(=O)CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1ccc(F)cc1
Show InChI InChI=1/C21H21F2NO3/c22-16-2-4-17(5-3-16)27-18-7-14-10-24(11-15(14)8-18)12-21(26)13-1-6-20(25)19(23)9-13/h1-6,9,14-15,18,25H,7-8,10-12H2/t14-,15+,18-
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 53.2n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370689
PNG
(US10239835, Example 00241)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1ccc(F)cc1
Show InChI InChI=1/C21H22FNO3/c22-17-3-7-19(8-4-17)26-20-9-15-11-23(12-16(15)10-20)13-21(25)14-1-5-18(24)6-2-14/h1-8,15-16,20,24H,9-13H2/t15-,16+,20-
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 53.4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370758
PNG
(US10239835, Example 00310)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)nc1
Show InChI InChI=1/C20H21FN2O3/c21-20-6-5-17(9-22-20)26-18-7-14-10-23(11-15(14)8-18)12-19(25)13-1-3-16(24)4-2-13/h1-6,9,14-15,18,24H,7-8,10-12H2/t14-,15+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 55.2n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370718
PNG
(US10239835, Example 00270)
Show SMILES COc1ccc(O[C@H]2C[C@H]3CN(CC(=O)c4ccc(O)cc4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H25NO4/c1-26-19-6-8-20(9-7-19)27-21-10-16-12-23(13-17(16)11-21)14-22(25)15-2-4-18(24)5-3-15/h2-9,16-17,21,24H,10-14H2,1H3/t16-,17+,21-
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 57.3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370683
PNG
(US10239835, Example 00235)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cc(F)cc(F)c1)c1ccc(O)cn1
Show InChI InChI=1/C20H22F2N2O3/c21-14-5-15(22)7-18(6-14)27-17-3-12-9-24(10-13(12)4-17)11-20(26)19-2-1-16(25)8-23-19/h1-2,5-8,12-13,17,20,25-26H,3-4,9-11H2/t12-,13+,17+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 58.3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370799
PNG
(US10239835, Example 00351)
Show SMILES Cc1ccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cn4)C[C@H]3C2)c(F)n1
Show InChI InChI=1/C20H24FN3O3/c1-12-2-5-19(20(21)23-12)27-16-6-13-9-24(10-14(13)7-16)11-18(26)17-4-3-15(25)8-22-17/h2-5,8,13-14,16,18,25-26H,6-7,9-11H2,1H3/t13-,14+,16+,18?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 60.2n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370677
PNG
(US10239835, Example 00229)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)c(F)c1
Show InChI InChI=1/C21H21F2NO3/c22-19-6-5-17(9-20(19)23)27-18-7-14-10-24(11-15(14)8-18)12-21(26)13-1-3-16(25)4-2-13/h1-6,9,14-15,18,25H,7-8,10-12H2/t14-,15+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 61.6n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370710
PNG
(US10239835, Example 00262)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cn4)C[C@H]3C2)cc1
Show InChI InChI=1/C21H26N2O4/c1-26-17-3-5-18(6-4-17)27-19-8-14-11-23(12-15(14)9-19)13-21(25)20-7-2-16(24)10-22-20/h2-7,10,14-15,19,21,24-25H,8-9,11-13H2,1H3/t14-,15+,19+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 65.8n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370701
PNG
(US10239835, Example 00253)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(cc1)C#N
Show InChI InChI=1/C22H22N2O3/c23-11-15-1-7-20(8-2-15)27-21-9-17-12-24(13-18(17)10-21)14-22(26)16-3-5-19(25)6-4-16/h1-8,17-18,21,25H,9-10,12-14H2/t17-,18+,21+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 68.2n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370742
PNG
(US10239835, Example 00294)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1ccc(F)c(F)c1
Show InChI InChI=1/C21H21F2NO3/c22-19-6-5-17(9-20(19)23)27-18-7-14-10-24(11-15(14)8-18)12-21(26)13-1-3-16(25)4-2-13/h1-6,9,14-15,18,25H,7-8,10-12H2/t14-,15+,18-
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 68.6n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370713
PNG
(US10239835, Example 00265)
Show SMILES COc1cccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cn4)C[C@H]3C2)c1
Show InChI InChI=1/C21H26N2O4/c1-26-17-3-2-4-18(9-17)27-19-7-14-11-23(12-15(14)8-19)13-21(25)20-6-5-16(24)10-22-20/h2-6,9-10,14-15,19,21,24-25H,7-8,11-13H2,1H3/t14-,15+,19+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 70.7n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370789
PNG
(US10239835, Example 00341)
Show SMILES Cc1cccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cc4)C[C@H]3C2)c1F
Show InChI InChI=1/C22H26FNO3/c1-14-3-2-4-21(22(14)23)27-19-9-16-11-24(12-17(16)10-19)13-20(26)15-5-7-18(25)8-6-15/h2-8,16-17,19-20,25-26H,9-13H2,1H3/t16-,17+,19+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 72.6n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370808
PNG
(US10239835, Example 00360)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Sc1ccc(F)cc1
Show InChI InChI=1/C21H22FNO2S/c22-17-3-7-19(8-4-17)26-20-9-15-11-23(12-16(15)10-20)13-21(25)14-1-5-18(24)6-2-14/h1-8,15-16,20,24H,9-13H2/t15-,16+,20+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 74n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370760
PNG
(US10239835, Example 00312)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)nc1)c1ccc(O)cc1
Show InChI InChI=1/C20H23FN2O3/c21-20-6-5-17(9-22-20)26-18-7-14-10-23(11-15(14)8-18)12-19(25)13-1-3-16(24)4-2-13/h1-6,9,14-15,18-19,24-25H,7-8,10-12H2/t14-,15+,18+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 74.1n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370790
PNG
(US10239835, Example 00342)
Show SMILES COc1cccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cc4)C[C@H]3C2)c1F
Show InChI InChI=1/C22H26FNO4/c1-27-20-3-2-4-21(22(20)23)28-18-9-15-11-24(12-16(15)10-18)13-19(26)14-5-7-17(25)8-6-14/h2-8,15-16,18-19,25-26H,9-13H2,1H3/t15-,16+,18+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 77.7n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370750
PNG
(US10239835, Example 00302)
Show SMILES OC(CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1ccc(F)c(F)c1)c1ccc(O)cc1
Show InChI InChI=1/C21H23F2NO3/c22-19-6-5-17(9-20(19)23)27-18-7-14-10-24(11-15(14)8-18)12-21(26)13-1-3-16(25)4-2-13/h1-6,9,14-15,18,21,25-26H,7-8,10-12H2/t14-,15+,18-,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 80.7n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370684
PNG
(US10239835, Example 00236)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccnc1
Show InChI InChI=1/C20H22N2O3/c23-17-5-3-14(4-6-17)20(24)13-22-11-15-8-19(9-16(15)12-22)25-18-2-1-7-21-10-18/h1-7,10,15-16,19,23H,8-9,11-13H2/t15-,16+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 81.5n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370720
PNG
(US10239835, Example 00272)
Show SMILES COc1ccc(O[C@H]2C[C@H]3CN(CC(O)c4ccc(O)c(F)c4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H26FNO4/c1-27-17-3-5-18(6-4-17)28-19-8-15-11-24(12-16(15)9-19)13-22(26)14-2-7-21(25)20(23)10-14/h2-7,10,15-16,19,22,25-26H,8-9,11-13H2,1H3/t15-,16+,19-,22?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 83.9n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370692
PNG
(US10239835, Example 00244)
Show SMILES Cc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cc4)C[C@H]3C2)cn1
Show InChI InChI=1/C21H24N2O3/c1-14-2-7-19(10-22-14)26-20-8-16-11-23(12-17(16)9-20)13-21(25)15-3-5-18(24)6-4-15/h2-7,10,16-17,20,24H,8-9,11-13H2,1H3/t16-,17+,20+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 84.5n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370724
PNG
(US10239835, Example 00276)
Show SMILES Cc1ccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)c(F)c4)C[C@H]3C2)cn1
Show InChI InChI=1/C21H25FN2O3/c1-13-2-4-17(9-23-13)27-18-6-15-10-24(11-16(15)7-18)12-21(26)14-3-5-20(25)19(22)8-14/h2-5,8-9,15-16,18,21,25-26H,6-7,10-12H2,1H3/t15-,16+,18+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 90n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370690
PNG
(US10239835, Example 00242)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccnc1)c1ccc(O)cc1
Show InChI InChI=1/C20H24N2O3/c23-17-5-3-14(4-6-17)20(24)13-22-11-15-8-19(9-16(15)12-22)25-18-2-1-7-21-10-18/h1-7,10,15-16,19-20,23-24H,8-9,11-13H2/t15-,16+,19+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 94.6n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370699
PNG
(US10239835, Example 00251)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)c(F)c4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H24FNO4/c1-27-17-3-5-18(6-4-17)28-19-8-15-11-24(12-16(15)9-19)13-22(26)14-2-7-21(25)20(23)10-14/h2-7,10,15-16,19,25H,8-9,11-13H2,1H3/t15-,16+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 102n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370725
PNG
(US10239835, Example 00277)
Show SMILES COc1ccc(O[C@H]2C[C@H]3CN(CC(O)c4ccc(O)cc4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H27NO4/c1-26-19-6-8-20(9-7-19)27-21-10-16-12-23(13-17(16)11-21)14-22(25)15-2-4-18(24)5-3-15/h2-9,16-17,21-22,24-25H,10-14H2,1H3/t16-,17+,21-,22?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 112n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370762
PNG
(US10239835, Example 00314)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)nc1)c1ccc(O)cn1
Show InChI InChI=1/C19H22FN3O3/c20-19-4-2-15(8-22-19)26-16-5-12-9-23(10-13(12)6-16)11-18(25)17-3-1-14(24)7-21-17/h1-4,7-8,12-13,16,18,24-25H,5-6,9-11H2/t12-,13+,16+,18?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 112n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370811
PNG
(US10239835, Example 00362)
Show SMILES COc1ccc(S[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cc4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H27NO3S/c1-26-19-6-8-20(9-7-19)27-21-10-16-12-23(13-17(16)11-21)14-22(25)15-2-4-18(24)5-3-15/h2-9,16-17,21-22,24-25H,10-14H2,1H3/t16-,17+,21+,22?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 113n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370788
PNG
(US10239835, Example 00340)
Show SMILES COc1cccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cc4)C[C@H]3C2)c1F
Show InChI InChI=1/C22H24FNO4/c1-27-20-3-2-4-21(22(20)23)28-18-9-15-11-24(12-16(15)10-18)13-19(26)14-5-7-17(25)8-6-14/h2-8,15-16,18,25H,9-13H2,1H3/t15-,16+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 117n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370730
PNG
(US10239835, Example 00282)
Show SMILES Cc1ncccc1O[C@@H]1C[C@H]2CN(CC(=O)c3ccc(O)cc3)C[C@H]2C1
Show InChI InChI=1/C21H24N2O3/c1-14-21(3-2-8-22-14)26-19-9-16-11-23(12-17(16)10-19)13-20(25)15-4-6-18(24)7-5-15/h2-8,16-17,19,24H,9-13H2,1H3/t16-,17+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 134n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370770
PNG
(US10239835, Example 00322)
Show SMILES COC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1ccc(O)cc1
Show InChI InChI=1/C22H26FNO3/c1-26-22(15-2-6-19(25)7-3-15)14-24-12-16-10-21(11-17(16)13-24)27-20-8-4-18(23)5-9-20/h2-9,16-17,21-22,25H,10-14H2,1H3/t16-,17+,21+,22?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 139n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370707
PNG
(US10239835, Example 00259)
Show SMILES Cc1ccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cc4)C[C@H]3C2)cn1
Show InChI InChI=1/C21H26N2O3/c1-14-2-7-19(10-22-14)26-20-8-16-11-23(12-17(16)9-20)13-21(25)15-3-5-18(24)6-4-15/h2-7,10,16-17,20-21,24-25H,8-9,11-13H2,1H3/t16-,17+,20+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 140n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370771
PNG
(US10239835, Example 00323)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cnccn1
Show InChI InChI=1/C19H21N3O3/c23-16-3-1-13(2-4-16)18(24)12-22-10-14-7-17(8-15(14)11-22)25-19-9-20-5-6-21-19/h1-6,9,14-15,17,23H,7-8,10-12H2/t14-,15+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 149n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370776
PNG
(US10239835, Example 00328)
Show SMILES COc1cccc(F)c1O[C@@H]1C[C@H]2CN(CC(O)c3ccc(O)cn3)C[C@H]2C1
Show InChI InChI=1/C21H25FN2O4/c1-27-20-4-2-3-17(22)21(20)28-16-7-13-10-24(11-14(13)8-16)12-19(26)18-6-5-15(25)9-23-18/h2-6,9,13-14,16,19,25-26H,7-8,10-12H2,1H3/t13-,14+,16+,19?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 163n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370786
PNG
(US10239835, Example 00338)
Show SMILES Cc1cccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cc4)C[C@H]3C2)c1F
Show InChI InChI=1/C22H24FNO3/c1-14-3-2-4-21(22(14)23)27-19-9-16-11-24(12-17(16)10-19)13-20(26)15-5-7-18(25)8-6-15/h2-8,16-17,19,25H,9-13H2,1H3/t16-,17+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 177n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370731
PNG
(US10239835, Example 00283)
Show SMILES Cc1ncccc1O[C@@H]1C[C@H]2CN(CC(O)c3ccc(O)cc3)C[C@H]2C1
Show InChI InChI=1/C21H26N2O3/c1-14-21(3-2-8-22-14)26-19-9-16-11-23(12-17(16)10-19)13-20(25)15-4-6-18(24)7-5-15/h2-8,16-17,19-20,24-25H,9-13H2,1H3/t16-,17+,19+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 188n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370738
PNG
(US10239835, Example 00290)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccc2cnccc12)c1ccc(O)cc1
Show InChI InChI=1/C24H26N2O3/c27-20-6-4-16(5-7-20)23(28)15-26-13-18-10-21(11-19(18)14-26)29-24-3-1-2-17-12-25-9-8-22(17)24/h1-9,12,18-19,21,23,27-28H,10-11,13-15H2/t18-,19+,21+,23?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 191n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370798
PNG
(US10239835, Example 00350)
Show SMILES Cc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cc4)C[C@H]3C2)c(F)c1
Show InChI InChI=1/C22H24FNO3/c1-14-2-7-22(20(23)8-14)27-19-9-16-11-24(12-17(16)10-19)13-21(26)15-3-5-18(25)6-4-15/h2-8,16-17,19,25H,9-13H2,1H3/t16-,17+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 210n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370761
PNG
(US10239835, Example 00313)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1F
Show InChI InChI=1/C20H21FN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,24H,7-8,10-12H2/t13-,14+,16+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 219n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370766
PNG
(US10239835, Example 00318)
Show SMILES Cc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cn4)C[C@H]3C2)c(F)c1
Show InChI InChI=1/C21H23FN2O3/c1-13-2-5-21(18(22)6-13)27-17-7-14-10-24(11-15(14)8-17)12-20(26)19-4-3-16(25)9-23-19/h2-6,9,14-15,17,25H,7-8,10-12H2,1H3/t14-,15+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 225n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370807
PNG
(US10239835, Example 00359)
Show SMILES COc1ccc(S[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cc4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H25NO3S/c1-26-19-6-8-20(9-7-19)27-21-10-16-12-23(13-17(16)11-21)14-22(25)15-2-4-18(24)5-3-15/h2-9,16-17,21,24H,10-14H2,1H3/t16-,17+,21+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 230n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370785
PNG
(US10239835, Example 00337)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cnccn1)c1ccc(O)cc1
Show InChI InChI=1/C19H23N3O3/c23-16-3-1-13(2-4-16)18(24)12-22-10-14-7-17(8-15(14)11-22)25-19-9-20-5-6-21-19/h1-6,9,14-15,17-18,23-24H,7-8,10-12H2/t14-,15+,17+,18?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 243n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370793
PNG
(US10239835, Example 00345)
Show SMILES COc1cccc(F)c1O[C@@H]1C[C@H]2CN(CC(O)c3ccc(O)cc3)C[C@H]2C1
Show InChI InChI=1/C22H26FNO4/c1-27-21-4-2-3-19(23)22(21)28-18-9-15-11-24(12-16(15)10-18)13-20(26)14-5-7-17(25)8-6-14/h2-8,15-16,18,20,25-26H,9-13H2,1H3/t15-,16+,18+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 249n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370719
PNG
(US10239835, Example 00271)
Show SMILES COc1ccc(O[C@H]2C[C@H]3CN(CC(=O)c4ccc(O)c(F)c4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H24FNO4/c1-27-17-3-5-18(6-4-17)28-19-8-15-11-24(12-16(15)9-19)13-22(26)14-2-7-21(25)20(23)10-14/h2-7,10,15-16,19,25H,8-9,11-13H2,1H3/t15-,16+,19-
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 250n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370685
PNG
(US10239835, Example 00237)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cncc(Cl)c1
Show InChI InChI=1/C20H21ClN2O3/c21-16-7-19(9-22-8-16)26-18-5-14-10-23(11-15(14)6-18)12-20(25)13-1-3-17(24)4-2-13/h1-4,7-9,14-15,18,24H,5-6,10-12H2/t14-,15+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 253n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370703
PNG
(US10239835, Example 00255)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cncc(F)c1)c1ccc(O)cc1
Show InChI InChI=1/C20H23FN2O3/c21-16-7-19(9-22-8-16)26-18-5-14-10-23(11-15(14)6-18)12-20(25)13-1-3-17(24)4-2-13/h1-4,7-9,14-15,18,20,24-25H,5-6,10-12H2/t14-,15+,18+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 267n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370780
PNG
(US10239835, Example 00332)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccc(F)c1F
Show InChI InChI=1/C20H20F2N2O3/c21-16-2-1-3-19(20(16)22)27-15-6-12-9-24(10-13(12)7-15)11-18(26)17-5-4-14(25)8-23-17/h1-5,8,12-13,15,25H,6-7,9-11H2/t12-,13+,15+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 308n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370695
PNG
(US10239835, Example 00247)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(cc1)C#N)c1ccc(O)c(F)n1
Show InChI InChI=1/C21H22FN3O3/c22-21-19(26)6-5-18(24-21)20(27)12-25-10-14-7-17(8-15(14)11-25)28-16-3-1-13(9-23)2-4-16/h1-6,14-15,17,20,26-27H,7-8,10-12H2/t14-,15+,17+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 367n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370737
PNG
(US10239835, Example 00289)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccc2cnccc12
Show InChI InChI=1/C24H24N2O3/c27-20-6-4-16(5-7-20)23(28)15-26-13-18-10-21(11-19(18)14-26)29-24-3-1-2-17-12-25-9-8-22(17)24/h1-9,12,18-19,21,27H,10-11,13-15H2/t18-,19+,21+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 409n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370696
PNG
(US10239835, Example 00248)
Show SMILES Oc1ccc(cc1F)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccnc1
Show InChI InChI=1/C20H21FN2O3/c21-18-8-13(3-4-19(18)24)20(25)12-23-10-14-6-17(7-15(14)11-23)26-16-2-1-5-22-9-16/h1-5,8-9,14-15,17,24H,6-7,10-12H2/t14-,15+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 434n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370773
PNG
(US10239835, Example 00325)
Show SMILES Cc1cccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cn4)C[C@H]3C2)c1F
Show InChI InChI=1/C21H23FN2O3/c1-13-3-2-4-20(21(13)22)27-17-7-14-10-24(11-15(14)8-17)12-19(26)18-6-5-16(25)9-23-18/h2-6,9,14-15,17,25H,7-8,10-12H2,1H3/t14-,15+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 435n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370739
PNG
(US10239835, Example 00291)
Show SMILES COc1ccc(O[C@H]2C[C@H]3CN(CC(O)c4ccc(O)cn4)C[C@H]3C2)cc1
Show InChI InChI=1/C21H26N2O4/c1-26-17-3-5-18(6-4-17)27-19-8-14-11-23(12-15(14)9-19)13-21(25)20-7-2-16(24)10-22-20/h2-7,10,14-15,19,21,24-25H,8-9,11-13H2,1H3/t14-,15+,19-,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 440n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370792
PNG
(US10239835, Example 00344)
Show SMILES COc1cccc(F)c1O[C@@H]1C[C@H]2CN(CC(=O)c3ccc(O)cc3)C[C@H]2C1
Show InChI InChI=1/C22H24FNO4/c1-27-21-4-2-3-19(23)22(21)28-18-9-15-11-24(12-16(15)10-18)13-20(26)14-5-7-17(25)8-6-14/h2-8,15-16,18,25H,9-13H2,1H3/t15-,16+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 466n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370686
PNG
(US10239835, Example 00238)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cncc(Cl)c1)c1ccc(O)cc1
Show InChI InChI=1/C20H23ClN2O3/c21-16-7-19(9-22-8-16)26-18-5-14-10-23(11-15(14)6-18)12-20(25)13-1-3-17(24)4-2-13/h1-4,7-9,14-15,18,20,24-25H,5-6,10-12H2/t14-,15+,18+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 493n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370777
PNG
(US10239835, Example 00329)
Show SMILES COc1ccc(F)c(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cn4)C[C@H]3C2)c1
Show InChI InChI=1/C21H25FN2O4/c1-27-16-3-4-18(22)21(8-16)28-17-6-13-10-24(11-14(13)7-17)12-20(26)19-5-2-15(25)9-23-19/h2-5,8-9,13-14,17,20,25-26H,6-7,10-12H2,1H3/t13-,14+,17+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 547n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370779
PNG
(US10239835, Example 00331)
Show SMILES COc1ccc(F)c(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)cc4)C[C@H]3C2)c1
Show InChI InChI=1/C22H26FNO4/c1-27-18-6-7-20(23)22(10-18)28-19-8-15-11-24(12-16(15)9-19)13-21(26)14-2-4-17(25)5-3-14/h2-7,10,15-16,19,21,25-26H,8-9,11-13H2,1H3/t15-,16+,19+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 569n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370778
PNG
(US10239835, Example 00330)
Show SMILES COc1ccc(F)c(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cc4)C[C@H]3C2)c1
Show InChI InChI=1/C22H24FNO4/c1-27-18-6-7-20(23)22(10-18)28-19-8-15-11-24(12-16(15)9-19)13-21(26)14-2-4-17(25)5-3-14/h2-7,10,15-16,19,25H,8-9,11-13H2,1H3/t15-,16+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 631n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370680
PNG
(US10239835, Example 00232)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1
Show InChI InChI=1/C20H21FN2O3/c21-15-1-4-17(5-2-15)26-18-7-13-10-23(11-14(13)8-18)12-20(25)19-6-3-16(24)9-22-19/h1-6,9,13-14,18,24H,7-8,10-12H2/t13-,14+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 699n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370796
PNG
(US10239835, Example 00348)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cncnc1
Show InChI InChI=1/C19H21N3O3/c23-16-3-1-13(2-4-16)19(24)11-22-9-14-5-17(6-15(14)10-22)25-18-7-20-12-21-8-18/h1-4,7-8,12,14-15,17,23H,5-6,9-11H2/t14-,15+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.04E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370764
PNG
(US10239835, Example 00316)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1c(F)cccc1F
Show InChI InChI=1/C20H20F2N2O3/c21-16-2-1-3-17(22)20(16)27-15-6-12-9-24(10-13(12)7-15)11-19(26)18-5-4-14(25)8-23-18/h1-5,8,12-13,15,25H,6-7,9-11H2/t12-,13+,15+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.08E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370763
PNG
(US10239835, Example 00315)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1F
Show InChI InChI=1/C20H20F2N2O3/c21-14-1-4-20(17(22)7-14)27-16-5-12-9-24(10-13(12)6-16)11-19(26)18-3-2-15(25)8-23-18/h1-4,7-8,12-13,16,25H,5-6,9-11H2/t12-,13+,16+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.15E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370679
PNG
(US10239835, Example 00231)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)c(F)c1
Show InChI InChI=1/C20H20F2N2O3/c21-17-3-2-15(7-18(17)22)27-16-5-12-9-24(10-13(12)6-16)11-20(26)19-4-1-14(25)8-23-19/h1-4,7-8,12-13,16,25H,5-6,9-11H2/t12-,13+,16+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.26E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370709
PNG
(US10239835, Example 00261)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)c(OC)n4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H28N2O5/c1-27-16-3-5-17(6-4-16)29-18-9-14-11-24(12-15(14)10-18)13-21(26)19-7-8-20(25)22(23-19)28-2/h3-8,14-15,18,21,25-26H,9-13H2,1-2H3/t14-,15+,18+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.33E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370795
PNG
(US10239835, Example 00347)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1Cl
Show InChI InChI=1/C20H21ClN2O3/c21-17-3-1-2-4-20(17)26-16-7-13-10-23(11-14(13)8-16)12-19(25)18-6-5-15(24)9-22-18/h1-6,9,13-14,16,24H,7-8,10-12H2/t13-,14+,16+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.66E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370704
PNG
(US10239835, Example 00256 | US10239835, Example 00...)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1cn[nH]c1
Show InChI InChI=1/C18H22FN3O2/c19-15-1-3-16(4-2-15)24-17-5-12-9-22(10-13(12)6-17)11-18(23)14-7-20-21-8-14/h1-4,7-8,12-13,17-18,23H,5-6,9-11H2,(H,20,21)/t12-,13+,17+,18?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.98E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370723
PNG
(US10239835, Example 00275)
Show SMILES Cc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)c(F)c4)C[C@H]3C2)cn1
Show InChI InChI=1/C21H23FN2O3/c1-13-2-4-17(9-23-13)27-18-6-15-10-24(11-16(15)7-18)12-21(26)14-3-5-20(25)19(22)8-14/h2-5,8-9,15-16,18,25H,6-7,10-12H2,1H3/t15-,16+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 2.37E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370728
PNG
(US10239835, Example 00280)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccncc1
Show InChI InChI=1/C20H22N2O3/c23-17-3-1-14(2-4-17)20(24)13-22-11-15-9-19(10-16(15)12-22)25-18-5-7-21-8-6-18/h1-8,15-16,19,23H,9-13H2/t15-,16+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 2.78E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370717
PNG
(US10239835, Example 00269)
Show SMILES OC(CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1cc(F)cc(F)c1)c1ccc(O)cn1
Show InChI InChI=1/C20H22F2N2O3/c21-14-5-15(22)7-18(6-14)27-17-3-12-9-24(10-13(12)4-17)11-20(26)19-2-1-16(25)8-23-19/h1-2,5-8,12-13,17,20,25-26H,3-4,9-11H2/t12-,13+,17-,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 2.92E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370733
PNG
(US10239835, Example 00285)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(O)c4ccc(O)c(F)n4)C[C@H]3C2)cc1
Show InChI InChI=1/C21H25FN2O4/c1-27-15-2-4-16(5-3-15)28-17-8-13-10-24(11-14(13)9-17)12-20(26)18-6-7-19(25)21(22)23-18/h2-7,13-14,17,20,25-26H,8-12H2,1H3/t13-,14+,17+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 3.29E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370803
PNG
(US10239835, Example 00355)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2CC(C[C@@H]2C1)S(=O)(=O)c1ccccc1
Show InChI InChI=1/C21H23NO4S/c23-18-8-6-15(7-9-18)21(24)14-22-12-16-10-20(11-17(16)13-22)27(25,26)19-4-2-1-3-5-19/h1-9,16-17,20,23H,10-14H2/t16-,17+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 3.50E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370783
PNG
(US10239835, Example 00335)
Show SMILES COc1cccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cn4)C[C@H]3C2)c1F
Show InChI InChI=1/C21H23FN2O4/c1-27-19-3-2-4-20(21(19)22)28-16-7-13-10-24(11-14(13)8-16)12-18(26)17-6-5-15(25)9-23-17/h2-6,9,13-14,16,25H,7-8,10-12H2,1H3/t13-,14+,16+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 3.78E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370804
PNG
(US10239835, Example 00356)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)S(=O)(=O)c1ccccc1)c1ccc(O)cc1
Show InChI InChI=1/C21H25NO4S/c23-18-8-6-15(7-9-18)21(24)14-22-12-16-10-20(11-17(16)13-22)27(25,26)19-4-2-1-3-5-19/h1-9,16-17,20-21,23-24H,10-14H2/t16-,17+,20+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 4.37E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370729
PNG
(US10239835, Example 00281)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccncc1)c1ccc(O)cc1
Show InChI InChI=1/C20H24N2O3/c23-17-3-1-14(2-4-17)20(24)13-22-11-15-9-19(10-16(15)12-22)25-18-5-7-21-8-6-18/h1-8,15-16,19-20,23-24H,9-13H2/t15-,16+,19+,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 4.47E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370704
PNG
(US10239835, Example 00256 | US10239835, Example 00...)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1cn[nH]c1
Show InChI InChI=1/C18H22FN3O2/c19-15-1-3-16(4-2-15)24-17-5-12-9-22(10-13(12)6-17)11-18(23)14-7-20-21-8-14/h1-4,7-8,12-13,17-18,23H,5-6,9-11H2,(H,20,21)/t12-,13+,17+,18?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 4.89E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370734
PNG
(US10239835, Example 00286)
Show SMILES Oc1ccc(cc1)C(=O)CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1cccnc1
Show InChI InChI=1/C20H22N2O3/c23-17-5-3-14(4-6-17)20(24)13-22-11-15-8-19(9-16(15)12-22)25-18-2-1-7-21-10-18/h1-7,10,15-16,19,23H,8-9,11-13H2/t15-,16+,19-
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 5.22E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370752
PNG
(US10239835, Example 00304)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccccc1
Show InChI InChI=1/C20H22N2O3/c23-16-6-7-19(21-10-16)20(24)13-22-11-14-8-18(9-15(14)12-22)25-17-4-2-1-3-5-17/h1-7,10,14-15,18,23H,8-9,11-13H2/t14-,15+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 6.24E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370726
PNG
(US10239835, Example 00278)
Show SMILES COc1ccc(O[C@H]2C[C@H]3CN(CC(=O)c4ccc(O)cn4)C[C@H]3C2)cc1
Show InChI InChI=1/C21H24N2O4/c1-26-17-3-5-18(6-4-17)27-19-8-14-11-23(12-15(14)9-19)13-21(25)20-7-2-16(24)10-22-20/h2-7,10,14-15,19,24H,8-9,11-13H2,1H3/t14-,15+,19-
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 7.10E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370735
PNG
(US10239835, Example 00287)
Show SMILES OC(CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1cccnc1)c1ccc(O)cc1
Show InChI InChI=1/C20H24N2O3/c23-17-5-3-14(4-6-17)20(24)13-22-11-15-8-19(9-16(15)12-22)25-18-2-1-7-21-10-18/h1-7,10,15-16,19-20,23-24H,8-9,11-13H2/t15-,16+,19-,20?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 8.00E+3n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370688
PNG
(US10239835, Example 00240)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1cnn(Cc2ccccc2)c1
Show InChI InChI=1/C25H28FN3O2/c26-22-6-8-23(9-7-22)31-24-10-19-14-28(15-20(19)11-24)17-25(30)21-12-27-29(16-21)13-18-4-2-1-3-5-18/h1-9,12,16,19-20,24-25,30H,10-11,13-15,17H2/t19-,20+,24+,25?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370751
PNG
(US10239835, Example 00303)
Show SMILES OC(CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1ccc(cc1)C#N)c1ccc(O)cn1
Show InChI InChI=1/C21H23N3O3/c22-9-14-1-4-18(5-2-14)27-19-7-15-11-24(12-16(15)8-19)13-21(26)20-6-3-17(25)10-23-20/h1-6,10,15-16,19,21,25-26H,7-8,11-13H2/t15-,16+,19-,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370715
PNG
(US10239835, Example 00267)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1cc(F)cc(F)c1
Show InChI InChI=1/C20H20F2N2O3/c21-14-5-15(22)7-18(6-14)27-17-3-12-9-24(10-13(12)4-17)11-20(26)19-2-1-16(25)8-23-19/h1-2,5-8,12-13,17,25H,3-4,9-11H2/t12-,13+,17-
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370741
PNG
(US10239835, Example 00293)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@@H](C[C@@H]2C1)Oc1ccc(cc1)C#N
Show InChI InChI=1/C21H21N3O3/c22-9-14-1-4-18(5-2-14)27-19-7-15-11-24(12-16(15)8-19)13-21(26)20-6-3-17(25)10-23-20/h1-6,10,15-16,19,25H,7-8,11-13H2/t15-,16+,19-
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370697
PNG
(US10239835, Example 00249)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cn4)C[C@H]3C2)cc1
Show InChI InChI=1/C21H24N2O4/c1-26-17-3-5-18(6-4-17)27-19-8-14-11-23(12-15(14)9-19)13-21(25)20-7-2-16(24)10-22-20/h2-7,10,14-15,19,24H,8-9,11-13H2,1H3/t14-,15+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370736
PNG
(US10239835, Example 00288)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccc(c1)C#N
Show InChI InChI=1/C21H21N3O3/c22-9-14-2-1-3-18(6-14)27-19-7-15-11-24(12-16(15)8-19)13-21(26)20-5-4-17(25)10-23-20/h1-6,10,15-16,19,25H,7-8,11-13H2/t15-,16+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370775
PNG
(US10239835, Example 00327)
Show SMILES COc1ccc(F)c(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cn4)C[C@H]3C2)c1
Show InChI InChI=1/C21H23FN2O4/c1-27-16-3-4-18(22)21(8-16)28-17-6-13-10-24(11-14(13)7-17)12-20(26)19-5-2-15(25)9-23-19/h2-5,8-9,13-14,17,25H,6-7,10-12H2,1H3/t13-,14+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370706
PNG
(US10239835, Example 00258)
Show SMILES COc1cccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cn4)C[C@H]3C2)c1
Show InChI InChI=1/C21H24N2O4/c1-26-17-3-2-4-18(9-17)27-19-7-14-11-23(12-15(14)8-19)13-21(25)20-6-5-16(24)10-22-20/h2-6,9-10,14-15,19,24H,7-8,11-13H2,1H3/t14-,15+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370691
PNG
(US10239835, Example 00243)
Show SMILES Oc1ccc(nc1F)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1
Show InChI InChI=1/C20H20F2N2O3/c21-14-1-3-15(4-2-14)27-16-7-12-9-24(10-13(12)8-16)11-19(26)17-5-6-18(25)20(22)23-17/h1-6,12-13,16,25H,7-11H2/t12-,13+,16+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370806
PNG
(US10239835, Example 00358)
Show SMILES OC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)S(=O)(=O)c1ccccc1)c1ccc(O)c(F)c1
Show InChI InChI=1/C21H24FNO4S/c22-19-10-14(6-7-20(19)24)21(25)13-23-11-15-8-18(9-16(15)12-23)28(26,27)17-4-2-1-3-5-17/h1-7,10,15-16,18,21,24-25H,8-9,11-13H2/t15-,16+,18+,21?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370687
PNG
(US10239835, Example 00239)
Show SMILES Fc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4cnn(Cc5ccccc5)c4)C[C@H]3C2)cc1
Show InChI InChI=1/C25H26FN3O2/c26-22-6-8-23(9-7-22)31-24-10-19-14-28(15-20(19)11-24)17-25(30)21-12-27-29(16-21)13-18-4-2-1-3-5-18/h1-9,12,16,19-20,24H,10-11,13-15,17H2/t19-,20+,24+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370732
PNG
(US10239835, Example 00284)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)c(F)n4)C[C@H]3C2)cc1
Show InChI InChI=1/C21H23FN2O4/c1-27-15-2-4-16(5-3-15)28-17-8-13-10-24(11-14(13)9-17)12-20(26)18-6-7-19(25)21(22)23-18/h2-7,13-14,17,25H,8-12H2,1H3/t13-,14+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370747
PNG
(US10239835, Example 00299)
Show SMILES COc1ncccc1O[C@@H]1C[C@H]2CN(CC(=O)c3ccc(O)cc3)C[C@H]2C1
Show InChI InChI=1/C21H24N2O4/c1-26-21-20(3-2-8-22-21)27-18-9-15-11-23(12-16(15)10-18)13-19(25)14-4-6-17(24)7-5-14/h2-8,15-16,18,24H,9-13H2,1H3/t15-,16+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370791
PNG
(US10239835, Example 00343)
Show SMILES Cc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)cn4)C[C@H]3C2)c(F)n1
Show InChI InChI=1/C20H22FN3O3/c1-12-2-5-19(20(21)23-12)27-16-6-13-9-24(10-14(13)7-16)11-18(26)17-4-3-15(25)8-22-17/h2-5,8,13-14,16,25H,6-7,9-11H2,1H3/t13-,14+,16+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370682
PNG
(US10239835, Example 00234)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cc(F)cc(F)c1
Show InChI InChI=1/C20H20F2N2O3/c21-14-5-15(22)7-18(6-14)27-17-3-12-9-24(10-13(12)4-17)11-20(26)19-2-1-16(25)8-23-19/h1-2,5-8,12-13,17,25H,3-4,9-11H2/t12-,13+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370708
PNG
(US10239835, Example 00260)
Show SMILES COc1ccc(O[C@@H]2C[C@H]3CN(CC(=O)c4ccc(O)c(OC)n4)C[C@H]3C2)cc1
Show InChI InChI=1/C22H26N2O5/c1-27-16-3-5-17(6-4-16)29-18-9-14-11-24(12-15(14)10-18)13-21(26)19-7-8-20(25)22(23-19)28-2/h3-8,14-15,18,25H,9-13H2,1-2H3/t14-,15+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370748
PNG
(US10239835, Example 00300)
Show SMILES COC(CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)cc1)c1ccc(OCc2ccccc2)cc1
Show InChI InChI=1/C29H32FNO3/c1-32-29(22-7-11-26(12-8-22)33-20-21-5-3-2-4-6-21)19-31-17-23-15-28(16-24(23)18-31)34-27-13-9-25(30)10-14-27/h2-14,23-24,28-29H,15-20H2,1H3/t23-,24+,28+,29?
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370753
PNG
(US10239835, Example 00305)
Show SMILES Oc1ccc(cc1F)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccnc1F
Show InChI InChI=1/C20H20F2N2O3/c21-16-8-12(3-4-17(16)25)18(26)11-24-9-13-6-15(7-14(13)10-24)27-19-2-1-5-23-20(19)22/h1-5,8,13-15,25H,6-7,9-11H2/t13-,14+,15+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370759
PNG
(US10239835, Example 00311)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(F)nc1
Show InChI InChI=1/C19H20FN3O3/c20-19-4-2-15(8-22-19)26-16-5-12-9-23(10-13(12)6-16)11-18(25)17-3-1-14(24)7-21-17/h1-4,7-8,12-13,16,24H,5-6,9-11H2/t12-,13+,16+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370774
PNG
(US10239835, Example 00326)
Show SMILES COc1cccc(F)c1O[C@@H]1C[C@H]2CN(CC(=O)c3ccc(O)cn3)C[C@H]2C1
Show InChI InChI=1/C21H23FN2O4/c1-27-20-4-2-3-17(22)21(20)28-16-7-13-10-24(11-14(13)8-16)12-19(26)18-6-5-15(25)9-23-18/h2-6,9,13-14,16,25H,7-8,10-12H2,1H3/t13-,14+,16+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370805
PNG
(US10239835, Example 00357)
Show SMILES Oc1ccc(cc1F)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)S(=O)(=O)c1ccccc1
Show InChI InChI=1/C21H22FNO4S/c22-19-10-14(6-7-20(19)24)21(25)13-23-11-15-8-18(9-16(15)12-23)28(26,27)17-4-2-1-3-5-17/h1-7,10,15-16,18,24H,8-9,11-13H2/t15-,16+,18+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370693
PNG
(US10239835, Example 00245)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(cc1)C#N
Show InChI InChI=1/C21H21N3O3/c22-9-14-1-4-18(5-2-14)27-19-7-15-11-24(12-16(15)8-19)13-21(26)20-6-3-17(25)10-23-20/h1-6,10,15-16,19,25H,7-8,11-13H2/t15-,16+,19+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370746
PNG
(US10239835, Example 00298)
Show SMILES Oc1ccc(nc1)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1cccnc1F
Show InChI InChI=1/C19H20FN3O3/c20-19-18(2-1-5-21-19)26-15-6-12-9-23(10-13(12)7-15)11-17(25)16-4-3-14(24)8-22-16/h1-5,8,12-13,15,24H,6-7,9-11H2/t12-,13+,15+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
GluN1/GluN2B NMDA receptor


(Homo sapiens (Human))
BDBM370700
PNG
(US10239835, Example 00252)
Show SMILES Oc1ccc(nc1F)C(=O)CN1C[C@@H]2C[C@H](C[C@@H]2C1)Oc1ccc(cc1)C#N
Show InChI InChI=1/C21H20FN3O3/c22-21-19(26)6-5-18(24-21)20(27)12-25-10-14-7-17(8-15(14)11-25)28-16-3-1-13(9-23)2-4-16/h1-6,14-15,17,26H,7-8,10-12H2/t14-,15+,17+
PDB
MMDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
GoogleScholar
PC cid
PC sid
UniChem
US Patent
n/an/a 1.00E+4n/an/an/an/an/an/a



CADENT THERAPEUTICS, INC.

US Patent


Assay Description
Cell Culture and plating: HEK293 cells expressing NR1/NR2B (Chantest, Cleveland, Ohio) were grown to 70-80% confluency as an adherent monolayer in st...


US Patent US10239835 (2019)

More data for this
Ligand-Target Pair
* indicates data uncertainty>20%